KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Equity Income (2017 - 2020)

Fulgent Genetics' Equity Income history spans 4 years, with the latest figure at $143000.0 for Q4 2020.

  • On a quarterly basis, Equity Income rose 182.18% to $143000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was -$488000.0, a 37.19% increase, with the full-year FY2020 number at -$488000.0, up 37.19% from a year prior.
  • Equity Income hit $143000.0 in Q4 2020 for Fulgent Genetics, up from -$189000.0 in the prior quarter.
  • Over the last five years, Equity Income for FLGT hit a ceiling of $143000.0 in Q4 2020 and a floor of -$279000.0 in Q1 2019.
  • Historically, Equity Income has averaged -$181600.0 across 4 years, with a median of -$193000.0 in 2020.
  • Biggest five-year swings in Equity Income: plummeted 134.29% in 2018 and later skyrocketed 182.18% in 2020.
  • Tracing FLGT's Equity Income over 4 years: stood at -$247000.0 in 2017, then rose by 5.26% to -$234000.0 in 2018, then grew by 25.64% to -$174000.0 in 2019, then skyrocketed by 182.18% to $143000.0 in 2020.
  • Business Quant data shows Equity Income for FLGT at $143000.0 in Q4 2020, -$189000.0 in Q3 2020, and -$193000.0 in Q2 2020.